Neal Browning receives a shot in the first-stage study of a potential vaccine for COVID-19, the disease caused by the new coronavirus, Monday, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle. Browning is the second patient to receive the shot in the study.
Ted S. Warren / AP Photo
Ted S. Warren / AP Photo
Neal Browning receives a shot in the first-stage study of a potential vaccine for COVID-19, the disease caused by the new coronavirus, Monday, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle. Browning is the second patient to receive the shot in the study.
The fall COVID-19 surge has arrived as predicted, and healthcare experts have learned a lot about the virus since the pandemic began. Outbreaks can happen anywhere and COVID-19 can sicken and kill anyone.
It has also been determined that certain pre-existing medical conditions can put a person at higher risk. But other factors for how sick you could become are often more difficult to quantify because that may be determined by your own immune response.
How does a person’s unique immune response protect them from or make them more susceptible to the Coronavirus? Appearing on Smart Talk Monday to discuss immunity and COVID-19 is Dr. Anita McElroy, MD, Ph.D., Center for Vaccine Research, University of Pittsburgh.
The U.S. Government initiated a public-private partnership called Operation Warp Speed to accelerate, manufacture and distribute vaccines faster than any other time in history.
It is an unprecedented strategy that has been called one of the “most ambitious scientific endeavors in modern U.S. history.”
How will we know that a fast-tracked vaccine is safe? Appearing on Smart Talk Monday to detail the rigorous vaccine process is FDA Commissioner Stephen Hahn.
This big news was met with a stock market surge and great enthusiasm by industry followers and global leaders, all betting on a vaccine distribution before 2021. A second COVID-19 vaccine made news today. The biotech company Moderna, Inc., reports their experimental vaccine was 94.5% effective in preventing disease, according to a data analysis of its clinical trial.
The news is encouraging and is positive for U.S. economic growth in the short run. Gus Faucher is the Chief Economist with PNC Financial Services Group and he appears on Smart Talk to share insights for a U.S. recovery.
The Associated Press and WITF’s democracy reporter Jordan Wilkie are partnering to tell stories about how Pennsylvania elections work, and to debunk misinformation surrounding elections.
